--- title: "Reduction Amyloid After Treatment IVIG for Mild impairment | Sutter Health" description: "Reduction of Amyloid in the Brain and Retina After Treatment With IVIG for Mild Cognitive Impairment" url: "https://www.sutterhealth.org/research/publications/reduction-amyloid-after-treatment-ivig-for-mild-impairment-1055312939" --- 1. [Home](https://www.sutterhealth.org/) / 2. [Research](https://www.sutterhealth.org/research) / 3. [Research publications](https://www.sutterhealth.org/research/publications) / 4. Reduction Amyloid After Treatment IVIG for Mild impairment # Reduction of Amyloid in the Brain and Retina After Treatment With IVIG for Mild Cognitive Impairment _American Journal of Alzheimer's Disease & Other Dementias_ 2020-02-12 ## Abstract Objective:To assess whether intravenous immunoglobulin (IVIG) in subjects with mild cognitive impairment (MCI) results in a reduction in amyloid in the central nervous system (CNS). Methods:Five subjects with MCI underwent baseline Florbetapir positron emission tomography and retinal autofluorescent imaging. All were administered IVIG (Octagam 10%) at 0.4 g/kg every 14 days for a total of 5 infusions. After 3 months, standard uptake value ratio (SUVR) and amyloid retinal deposits were reassessed. Results:Three subjects had a reduction in amyloid SUVR and all 5 subjects had a reduction in amyloid retinal deposits in at least 1 eye. Conclusions:A short course of IVIG over 2 months removes a measurable amount of amyloid from the CNS in persons with MCI. [PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/32048858/) ![Shawn J Kile, M.D.](https://dyn.mktgcdn.com/p/q0wjBudDBEScUW_Fehb6xrCnhqVyTm2ZGn3nY5fkqXc/fit=crop,gravity=auto,dpr=2,width=188,height=250,quality=100) Shawn J Kile, M.D. Principal investigator [View profile](https://www.sutterhealth.org/research/investigators/shawn-j-kile-md-1049681124) ![Carol Parise, Ph.D.](https://www.sutterhealth.org/static/images/sutter-fallback-image-3-4.jpg) Carol Parise, Ph.D. Principal investigator [View profile](https://www.sutterhealth.org/research/investigators/carol-parise-phd-1049681206) ## Research topics - [Alzheimer's Disease](https://www.sutterhealth.org/research-search-results?query=%22%5C%22Alzheimer%27s+Disease%5C%22%22) ## Related publications [View all publications](https://www.sutterhealth.org/research-search-results?verticalKey=research_publication) - Publication ### [Five-year outcomes after IVIG for mild cognitive impairment due to alzheimer disease](https://www.sutterhealth.org/research/publications/outcome-after-ivig-for-cognitive-impairment-due-to-alzheimer-1055312927) BMC Neuroscience 2099 Dec 31 - Publication ### [IVIG treatment of mild cognitive impairment due to Alzheimer's disease: a randomised double-blinded exploratory study of the effect on brain atrophy, cognition and conversion to dementia](https://www.sutterhealth.org/research/publications/ivig-treatment-of-mild-cognitive-impairment-1055312456) Relkin NR, Szabo P, Adamiak B, Burgut T, Monthe C, Lent RW, Younkin S, Younkin L, Schiff R, Weksler ME. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging. 2009 Nov;30(11):1728-36. doi: 10.1016/j.neurobiolaging.2007.12.021. Epub 2008 Feb 21. J Neurol Neurosurg Psychiatry. 2015 Sep 29. pii: jnnp-2015-311486. doi: 10.1136/jnnp-2015-311486. 2015 Sep 29 - Publication ### [Alzheimer abnormalities of the amygdala with Klüver-Bucy syndrome symptoms: an amygdaloid variant of Alzheimer disease](https://www.sutterhealth.org/research/publications/alzheimer-abnormalities-of-the-amygdala-1055312743) Arch Neurol. 2009 Jan;66(1):125-9. doi: 10.1001/archneurol.2008.517. Alzheimer abnormalities of the amygdala with Klüver-Bucy syndrome symptoms: an amygdaloid variant of Alzheimer disease. Kile SJ1, Ellis WG, Olichney JM, Farias S, DeCarli C. Author information 1Department of Neurology, University of California at Davis Arch Neurol. 2009 Jan; 2009 Jan 20 [View all publications](https://www.sutterhealth.org/research-search-results?verticalKey=research_publication) ```json {"@context":"https://schema.org","@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org","logo":"https://www.sutterhealth.org/static/images/sutter-health-logo.svg","address":{"@type":"PostalAddress","streetAddress":"2200 River Plaza Drive","addressLocality":"Sacramento","addressRegion":"CA","postalCode":"95833","addressCountry":"US"},"areaServed":{"@type":"AdministrativeArea","name":"California"},"sameAs":["https://www.facebook.com/SutterHealth","https://www.instagram.com/sutterhealth/","https://x.com/SutterHealth","https://www.youtube.com/sutterhealth","https://www.linkedin.com/company/sutter-health","https://en.wikipedia.org/wiki/Sutter_Health"]} ``` ```json {"@context":"https://schema.org","@type":"BreadcrumbList","@id":"https://www.sutterhealth.org/research/publications/reduction-amyloid-after-treatment-ivig-for-mild-impairment-1055312939#breadcrumblist","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://www.sutterhealth.org/"},{"@type":"ListItem","position":2,"name":"Research","item":"https://www.sutterhealth.org/research"},{"@type":"ListItem","position":3,"name":"Research publications","item":"https://www.sutterhealth.org/research/publications"},{"@type":"ListItem","position":4,"name":"Reduction Amyloid After Treatment IVIG for Mild impairment"}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalScholarlyArticle","@id":"https://www.sutterhealth.org/research/publications/reduction-amyloid-after-treatment-ivig-for-mild-impairment-1055312939#medicalscholarlyarticle","name":"Reduction of Amyloid in the Brain and Retina After Treatment With IVIG for Mild Cognitive Impairment","headline":"Reduction Amyloid After Treatment IVIG for Mild impairment","abstract":"Objective:To assess whether intravenous immunoglobulin (IVIG) in subjects with mild cognitive impairment (MCI) results in a reduction in amyloid in the central nervous system (CNS). Methods:Five subjects with MCI underwent baseline Florbetapir positron emission tomography and retinal autofluorescent imaging. All were administered IVIG (Octagam 10%) at 0.4 g/kg every 14 days for a total of 5 infusions. After 3 months, standard uptake value ratio (SUVR) and amyloid retinal deposits were reassessed. Results:Three subjects had a reduction in amyloid SUVR and all 5 subjects had a reduction in amyloid retinal deposits in at least 1 eye. Conclusions:A short course of IVIG over 2 months removes a measurable amount of amyloid from the CNS in persons with MCI.","description":"Reduction of Amyloid in the Brain and Retina After Treatment With IVIG for Mild Cognitive Impairment","keywords":["Alzheimer's Disease"],"datePublished":"2020-02-12","url":"https://www.sutterhealth.org/research/publications/reduction-amyloid-after-treatment-ivig-for-mild-impairment-1055312939","inLanguage":"en-US","identifier":[{"@type":"PropertyValue","propertyID":"PMID","value":"32048858"}],"sameAs":["https://pubmed.ncbi.nlm.nih.gov/32048858/"],"isPartOf":{"@type":"Periodical","name":"American Journal of Alzheimer's Disease & Other Dementias"},"about":[{"@type":"DefinedTerm","name":"Alzheimer's Disease","url":"https://www.sutterhealth.org/research-search-results?facets=%5B%7B%22i%22%3A%22c_researchTopics.name%22%2C%22v%22%3A%5B%22Alzheimer%27s+Disease%22%5D%7D%5D&verticalKey=research_publication"}],"mainEntityOfPage":{"@type":"WebPage","@id":"https://www.sutterhealth.org/research/publications/reduction-amyloid-after-treatment-ivig-for-mild-impairment-1055312939","breadcrumb":{"@id":"https://www.sutterhealth.org/research/publications/reduction-amyloid-after-treatment-ivig-for-mild-impairment-1055312939#breadcrumblist"}}} ```